1. CMU Intellectual Repository

Browsing by Author Masahiro Fukuoka

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 7 of 7
Issue DateTitleAuthor(s)
20-Jul-2011Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)Masahiro Fukuoka; Yi Long Wu; Sumitra Thongprasert; Patrapim Sunpaweravong; Swan Swan Leong; Virote Sriuranpong; Tsu Yi Chao; Kazuhiko Nakagawa; Da Tong Chu; Nagahiro Saijo
1-Feb-2017Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLCYi Long Wu; Nagahiro Saijo; Sumitra Thongprasert; J. C.H. Yang; Baohui Han; Benjamin Margono; Busayamas Chewaskulyong; Patrapim Sunpaweravong; Yuichiro Ohe; Yukito Ichinose; Jin Ji Yang; Tony S.K. Mok; Helen Young; Vincent Haddad; Yuri Rukazenkov; Masahiro Fukuoka
3-Sep-2009Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaTony S. Mok; Yi Long Wu; Sumitra Thongprasert; Chih Hsin Yang; Da Tong Chu; Nagahiro Saijo; Patrapim Sunpaweravong; Baohui Han; Benjamin Margono; Yukito Ichinose; Yutaka Nishiwaki; Yuichiro Ohe; Jin Ji Yang; Busyamas Chewaskulyong; Haiyi Jiang; Emma L. Duffield; Claire L. Watkins; Alison A. Armour; Masahiro Fukuoka
1-Jun-2017Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall SurvivalChee Khoon Lee; Lucy Davies; Yi Long Wu; Tetsuya Mitsudomi; Akira Inoue; Rafael Rosell; Caicun Zhou; Kazuhiko Nakagawa; Sumitra Thongprasert; Masahiro Fukuoka; Sally Lord; Ian Marschner; Yu Kang Tu; Richard J. Gralla; Val Gebski; Tony Mok; James Chih Hsin Yang
1-Jan-2011Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS)Sumitra Thongprasert; Emma Duffield; Nagahiro Saijo; Yi Long Wu; James Chih Hsin Yang; Da Tong Chu; Meilin Liao; Yuh Min Chen; Han Pin Kuo; Shunichi Negoro; Kwok Chi Lam; Alison Armour; Patrick Magill; Masahiro Fukuoka
1-Sep-2010Lung cancer working group reportNagahiro Saijo; Masahiro Fukuoka; Sumitra Thongprasert; Yukito Ichinose; Tetsuya Mitsudomi; Tony Shu Kam Mok; Yuichiro Ohe; Keunchil Park; Yi Long Wu
1-Aug-2013Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS studyYi Long Wu; Masahiro Fukuoka; Tony S.K. Mok; Nagahiro Saijo; Sumitra Thongprasert; James C.H. Yang; Da Tong Chu; Jin Ji Yang; Yuri Rukazenkov
Showing results 1 to 7 of 7